ATRIAL FIBRILLATION MANAGEMENT MADE EASY

ATRIAL FIBRILLATION MANAGEMENT MADE EASY

By: Kimberly Harris, MSN, FNP-C, RN

BACKGROUND AND RISK FACTORS

Overview

• What is Atrial Fibrillation?

• Pathophysiology

• Prevalence and Risk Factors

• Types of Atrial Fibrillation

• Clinical Presentation

• Diagnosis

• Workup and Testing

• Medication Management

• Procedure and Surgical Treatment Options

• Complications and Mortality

WHAT IS ATRIAL FIBRILLATION?

• Definition:

  • Atrial Fibrillation (AF) is recognized as the most commonly occurring arrhythmia.

• Electrocardiographic Characteristics:

  • RR intervals are not repetitive; described as "irregularly irregular."

  • Distinct P waves are absent.

  • The atrial cycle length (P-P interval) is irregular and typically less than 200 milliseconds, leading to an atrial rate exceeding 300 beats per minute.

PATHOPHYSIOLOGY

• Two mechanisms identified for triggering and maintaining AF:

  • Enhanced Automaticity:

  • Occurs in one or more polarizing foci located within the pulmonary veins.

  • Reentry:

  • Involves abnormal circuits created by atypical atrial tissue that sustain the arrhythmia.

PREVALENCE

• Global Health Issue:

  • There is increasing incidence and prevalence of AF worldwide.

  • In 2010, an estimated 33.5 million individuals were diagnosed with AF.

• Age:

  • AF is rare in infants and children; if present, it often coincides with structural heart defects.

  • The occurrence of AF rises with age.

  • A US study reported an overall prevalence of 1%, with 70% of those being at least 65 years old and 45% being older than 75 years.

  • Prevalence rates range from 0.1% in adults under 55 to 9% in those over 80 years of age.

SEX AND RACE PREVALENCE

• Sex:

  • AF is more prevalent in men compared to women (1.1% vs. 0.8%), consistent across all age groups.

• Race:

  • More frequently diagnosed in whites than in African Americans over the age of 50 (2.2% vs. 1.5%).

• Geographic Distribution:

  • Highest prevalence of AF observed in North America, with lower rates in Japan and South Korea.

RISK FACTORS

• Chronic Disease Associations:

  • Hypertensive Heart Disease:

  • Present in 6-10% of patients with acute myocardial infarction (MI) or heart failure (HF).

  • Associated with atrial ischemia or atrial stretching due to HF.

  • Lower incidence in patients with stable chronic coronary artery disease (CAD).

  • Valvular Heart Disease:

  • Mitral Valve Prolapse and Rheumatic Heart Disease.

• Heart Failure:

  • AF frequently coexists with HF, each potentially predisposing patients to the other.

  • The incidence of AF varies based on HF severity.

• Hypertrophic Cardiomyopathy:

  • Occurs in 10-28% of patients.

• Congenital Heart Disease:

  • About 20% of adults with atrial septal defects have AF, and the prevalence increases with age.

  • Post-surgical corrections of defects like ventricular septal defects or tetralogy of Fallot may lead to increased AF incidence.

• Venous Thromboembolic Disease.

• Obstructive Sleep Apnea.

• Obesity.

• Diabetes.

• Metabolic Syndrome.

• Chronic Kidney Disease.

POTENTIALLY REVERSIBLE TRIGGERS OF AF

• Surgery:

  • Highest incidence in patients undergoing cardiac surgery (CABG, valve surgeries, cardiac transplantation).

  • The perioperative incidence of AF is 4.1%, primarily within the initial 3 days post-surgery.

• Hyperthyroidism:

  • Increased beta adrenergic tone contributes to enhanced AF incidence and may lead to rapid ventricular response (RVR).

• Additional Triggers Include:

  • Family History

  • Genetic Factors

  • Inflammation and Infection

  • Pericardial Fat

  • Autonomic Dysfunction

  • Alcoholism

CLINICAL IMPLICATION OF AF

• Physiological Effects:

  • Loss of coordinated atrial contraction.

  • Rapid ventricular response affecting diastolic filling.

  • Blood stasis contributing to atrial clot formation.

  • Additional outcomes include:

  • Tachycardia leading to decreased cardiac output.

  • Increased morbidity and mortality.

  • Elevated risk of thromboembolism and strokes.

CLASSIFICATION AND CLINICAL PRESENTATION

Classification of AF

• AF is generally seen as a progressive disease categorized into:

  • Paroxysmal AF:

  • Intermittent episodes that terminate spontaneously or via intervention within 7 days.

  • Recurrence of episodes occurs with variable frequency.

  • Persistent AF:

  • Lasts longer than 7 days and often requires pharmacological or electrical cardioversion for rhythm restoration.

  • Long-standing Persistent AF:

  • Duration exceeds 12 months.

  • Permanent (Chronic) AF:

  • Resistant to cardioversion or pharmacological interventions.

  • A mutual decision is made by the physician and patient not to pursue rhythm control.

  • Post-operative AF:

  • Triggered by an underlying condition or event (MI, cardiac surgery, pulmonary disease, hyperthyroidism).

Clinical Presentation

• AF showcases a wide range of clinical presentations:

  • Asymptomatic:

  • Possible Symptoms Include:

  • Palpitations

  • Dyspnea

  • Fatigue

  • Lightheadedness

  • Chest Pain

  • Tachycardia

  • Weakness

  • Reduced exercise capacity

  • Symptoms are often nonspecific making the onset of AF difficult to determine.

  • If ECG does not show AF but suspicion exists, a Holter or event monitor may be utilized to document occurrences.

CLINICAL EVALUATION

• For Suspected Patients:

  • ECG:

  • Identifies current rhythm.

  • Echocardiogram:

  • Reveals heart size, chamber sizes, ejection fraction, valvular integrity, wall motion abnormalities, and systolic/diastolic function, including pericardial disease.

  • Cardiac Enzymes:

  • (TNI, CK, CK-MB): used to exclude MI.

  • Chest X-ray:

  • Assesses for pulmonary diseases (pneumonia, CHF, COPD).

  • CMP, Magnesium, CBC, and TSH:

  • Rule out anemia, infection, electrolyte imbalances, or thyroid issues.

PHARMACOLOGIC MANAGEMENT STRATEGIES

Management

• Rate Control:

  • Recommended for most patients to improve diastolic filling and coronary perfusion.

  • Aiming for heart rate (HR) <110 bpm in AF patients.

• Medications for Rate Control:

  • Beta Blockers: (e.g., metoprolol, carvedilol, esmolol, propranolol, labetalol).

  • Calcium Channel Blockers (CCB): (e.g., diltiazem, verapamil).

  • Digoxin:

  • Not a first-line agent, but can be utilized with beta blockers or CCBs to enhance vagal tone and slow ventricular rate.

Rhythm Control vs. Rate Control

• Factors Determining Approach:

  • Age, symptoms interfering with quality of life, side effects of antiarrhythmic therapies.

• Before Rhythm Control Initiation:

  • It is vital to address all risk factors for AF to optimize success.

• Antiarrhythmics:

  • Amiodarone (Pacerone)

  • Dofetilide (Tikosyn)

  • Flecainide (Tambocor)

  • Propafenone (Rhythmol)

  • Sotalol (Betapace)

  • Dronedarone (Multaq)

SELECTING AN ANTIARRHYTHMIC

Amiodarone

• Efficacy:

  • High likelihood of maintaining sinus rhythm; associated with significant long-term side effects including bradycardia, hypothyroidism, hyperthyroidism, pulmonary toxicity, ocular deposits, and elevated liver function tests.

• Monitoring:

  • Routine ECG, TSH, LFTs, chest X-ray, and eye exams are recommended.

AF without Structural Heart Disease

• First-Line Choices:

  • Flecainide or Propafenone due to lower side effects, efficacy, and ease of use.

  • Amiodarone, Dronedarone, Sotalol, and Dofetilide are viable alternatives as well.

AF with Structural Disease

• Recommended:

  • Dronedarone or Sotalol preferred over Amiodarone or Dofetilide.

• Coronary Artery Disease (CAD):

  • Choose from Sotalol, Dronedarone, Dofetilide, or Amiodarone, ideally Sotalol due to reduced side effects.

  • Flecainide and Propafenone are contraindicated due to increased mortality.

Heart Failure Considerations

• Preferred Medications:

  • Amiodarone or Dofetilide in those with active HF or ejection fraction (EF) <35%.

  • Avoid Sotalol, Propafenone, Dronedarone, and Flecainide as they can increase mortality.

Left Ventricular Hypertrophy (LVH)

• Increased risk for proarrhythmias in patients with significant LVH due to underlying ischemia.

  • Sotalol, Flecainide, and Propafenone carry higher risks.

  • Dronedarone considered relatively safe, Amiodarone as another option.

Drug-Resistant AF

• Recommendations:

  • Combination antiarrhythmic therapy is not advised.

  • Patients should be managed with rate control or referred for nonpharmacological therapy.

MANAGEMENT OF ANTIARRHYTHMICS

• Dosing:

  • Initial and subsequent dosages determined by the prescribing physician tailored to patient needs.

• Administration:

  • Inpatient vs. outpatient considerations addressed.

• Key Concerns:

  • Risks of bradycardia and proarrhythmia include VT, VF, or torsades.

  • Adverse reactions such as QT prolongation, heart failure, rapid rates, conduction abnormalities, hypotension, or stroke are potential side effects.

• Monitoring:

  • ECG monitoring recommended, especially in the first 24 hours after initiation in patients with a history of MI due to an 10-15% chance of adverse events.

Outpatient Considerations

• Initiation Recommendations:

  • Flecainide or Propafenone can be started in outpatient settings for patients without structural heart disease and normal baseline measurements.

  • Amiodarone or Dronedarone may be considered under the same conditions but require monitoring for risk factors including torsades and conduction issues.

  • Dronedarone and Amiodarone can serve patients in AF as outpatient therapy.

  • Patients with ICDs may be suitable for outpatient therapy owing to protective measures against proarrhythmias.

DRUG-RELATED ARRHYTHMIAS AND MORTALITY

• Risks of Antiarrhythmics:

  • These medications increase risks for life-threatening side effects.

  • Primary concerns include proarrhythmias, tachyarrhythmias, or bradycardia.

• Proarrhythmias:

  • All antiarrhythmics have the potential to induce proarrhythmias, particularly when patients develop CAD or HF.

• Bradyarrhythmias:

  • Generally caused by Amiodarone and Dronedarone with sinus bradycardia and AV nodal blockage reported in about 5% of cases.

  • Patients may require permanent pacemaker placement for continued use of these medications.

ANTIARRHYTHMIC FOLLOW-UPS

• Follow-Up Recommendations:

  • ECG check suggested one week post initiation of any antiarrhythmic.

  • Follow-up visits every 6 to 12 months to monitor QT intervals.

  • Routine evaluations of TSH, LFTs, chest X-ray, and eye examinations needed for those on Amiodarone.

ANTICOAGULATION CONSIDERATIONS

Anticoagulation

• CHA2DS2-VASc Score:

  • Tool for calculating stroke risk factors:

  • CHF +1 point

  • HTN +1 point

  • Age >75 +2 points

  • Age 65-74 +1 point

  • Diabetes Mellitus +1 point

  • Prior Stroke or TIA +1 point

  • Vascular Disease (MI, PAD, aortic plaque) +1 point

  • Female +1 point

  • A score of 2 or greater indicates the need for anticoagulation to mitigate stroke risk unless contraindicated (e.g., frequent falls, bleeding).

  • Lifelong anticoagulation is generally recommended unless contraindicated.

CHA2DS2-VASc vs. CHADS2

• CHADS2 Risk Score:

  • CHA2DS2-VASc Score:

  • CHF: 1 point

  • Hypertension: 1 point

  • Age > 75: 2 points

  • Age 65-74: 1 point

  • Diabetes: 1 point

  • Stroke/TIA/Thromboembolism: 2 points

  • Vascular disease: 1 point

  • Female: 1 point

ANNUAL STROKE RATE BY CHA2DS2-VASc

• CHA2DS2-VASc Annual Stroke Rate:

  • Stroke risk varies based on score:

  • Score 0 = 0%

  • Score 1 = 1.3%

  • Score 2 = 2.2%

  • Score 3 = 3.7%

  • Score 4 = 8.7%

  • Score 5 = 12.5%

  • Score 6 = 19.8%

HAS-BLED SCORE

• Usage:

  • Assess major bleeding risk in anticoagulated patients.

  • Hypertension

  • Renal disease

  • Liver disease

  • History of stroke

  • Prior major bleeding or predisposition to bleeding

  • Labile INR

  • Age >65

  • Medication use that increases bleeding risk (NSAIDs, Plavix).

• HAS-BLED Score:

  • Conditions granting points:

  • H-Hypertension: 1 point

  • A-Abnormal renal or liver function: 1 point

  • S-Stroke: 1 point

  • B-Bleeding tendency: 1 point

  • L-Labile INR: 1 point

  • E-Elderly (>65 years): 1 point

  • D-Drugs or alcohol use: 1 point

ANTICOAGULATION MEDICATIONS

• Coumadin (Warfarin):

  • INR goal 2-3.

  • Easily reversible with food restrictions and frequent blood tests required.

• Xarelto (Rivaroxaban):

  • 20 mg daily (15 mg for renal patients).

  • Does not require blood tests or dietary restrictions.

  • A reversal agent is available but expensive.

• Eliquis (Apixaban):

  • 5 mg twice daily; 2.5 mg twice daily for patients with at least two of the following:

  • Age ≥80

  • Weight <60 kg

  • Creatinine >1.5 mg/dL

• Dabigatran (Pradaxa):

  • 150 mg twice daily required.

NON-PHARMACOLOGIC TREATMENT STRATEGIES

Non-Pharmacologic Treatments

• Cardioversion

• Catheter Ablation

• MAZE Procedure

• AV Nodal Ablation

Cardioversion

• Purpose:

  • Restore normal sinus rhythm in cases where AF does not terminate spontaneously.

• Procedure:

  • Electric shock delivered to the heart to restore rhythm.

• Contraindications:

  • Asymptomatic patients with comorbid conditions and poor prognosis.

  • Inability to receive anticoagulation.

  • Identified thrombus on TEE.

  • Prior failed cardioversion or AF present over one year.

  • Markedly enlarged left atrium.

  • Recurrences while on adequate antiarrhythmic therapies.

Cardioversion Considerations

• Pre-therapy considerations include:

  • Rate Control:

  • Rapid rates managed with beta blockers or CCBs.

  • Anticoagulation:

  • Routine for most patients prior to cardioversion to reduce complications.

  • Timing:

  • Urgent cardiovert for hemodynamically unstable patients with intravenous heparin if oral anticoagulation is not optimized.

Cardioversion Success

• Effectiveness of the procedure is high, exceeding 90%, although it decreases with prolonged AF duration.

• Patients may undergo the procedure without antiarrhythmics to prevent AF recurrence, though medications may be utilized beforehand for enhancing success.

• Fasting for at least 6 hours prior to the procedure is required, along with stable oxygen saturation and serum potassium levels.

• A transesophageal echocardiogram is performed to assess for thrombus.

Complications of Cardioversion

• Following the procedure, significant adverse events are rare (e.g., respiratory distress, myocardial necrosis, skin burns).

• LV function may improve or normalize post-procedure.

• AF recurrence risk is heightened in patients with past AF episodes, larger left atrium sizes, structural heart conditions, or prior HF.

• Bradyarrhythmias can emerge post-cardioversion particularly in patients on rate control meds, older cohorts exhibiting tachy-brady syndrome, or patients with pre-existing bradycardia.

Catheter Ablation

• Purpose:

  • For symptomatic AF patients where medications are inadequate or intolerable.

• Anticoagulation:

  • Required for 2-3 months after the procedure, possibly lifelong.

• Effectiveness Rate:

  • 70-75% of patients are symptom-free at one year, but 50% may experience detectable AF.

• Challenges:

  • Lower success in long-standing AF extending beyond 1 year.

  • Major complications (vascular access problems, stroke) in up to 4% patients.

Types of Ablation

• Radiofrequency Ablation:

  • Utilizes heat.

• Cryothermal Ablation:

  • Uses cold techniques.

• Catheters are navigated to the heart via femoral vein under x-ray guidance, mapping electrical pathways and creating targeted scars to prevent AF conduction.

MAZE Procedure

• Initiated:

  • In the 1980s, aiming to create a "maze" of functional myocardium to facilitate atrial depolarization while reducing AF microreentry.

• Common Usage:

  • Performed during other cardiac surgeries, such as CABG or mitral valve surgery.

• Cox Maze IV:

  • The most recognized MAZE technique characterized by linear scars.

• Potential Complication:

  • The patient may need pacemaker implantation due to sinus node dysfunction.

AV Nodal Ablation

• Procedure Insight:

  • Radiofrequency ablation of the AV node and/or HIS bundle, resulting in complete AV block requiring pacemaker implantation.

  • Reserved for patients unable to tolerate rate control therapies, particularly in tachycardia-induced cardiomyopathy scenarios.

• Patient Outcomes:

  • Quality of life significantly enhanced for patients post-ablation.

• Types of Pacemakers:

  • Single Chamber Pacemaker:

  • Recommended for patients with permanent AF.

  • Dual Chamber Pacemaker:

  • Preferred for paroxysmal AF patients, maintaining AV synchrony during periods of sinus rhythm.

  • Notably, while AV nodal ablation provides better heart rate control, it doesn’t prevent AF, making long-term anticoagulation necessary to minimize stroke risk.

COMPLICATIONS, MORTALITY, AND CONCLUSION

Complications and Mortality

• Common complications from AF include:

  • Systemic Embolization:

  • Particularly strokes.

  • Cognitive Impairment and Dementia.

  • Heart Failure:

  • Generally due to tachycardia-induced cardiomyopathy.

  • Myocardial Infarction and Cardiac Arrest.

• Mortality Rate:

  • Studies indicate that AF doubles the death risk for both genders, largely due to associated risk factors like HF and stroke rather than AF alone.

  • Higher morbidity and mortality are observed in patients with significant symptom burden.

Long-Term Outcomes

• General Prognosis:

  • About 90% of patients will experience recurrent AF episodes, which may not always present with symptoms.

• Treatment Goals:

  • Strategies focus on reducing mortality and stroke risk, with early intervention shown to improve outcomes and enhance chances for successful sinus rhythm maintenance.

REFERENCES

• Ganz, L. I., MD, & Spragg, D., MD. (2020, January 8). Epidemiology of and risk factors for atrial fibrillation. Retrieved from https://www.uptodate.com.contents/epidemiology-of-and-risk-factors-for-atrial-fibrillation/

• Ganz, L. I., MD. (2018, April 3). Control of ventricular rate in atrial fibrillation: Nonpharmacologic therapy. Retrieved from https://www.uptodate.com/contents/control-of-ventricular-rate-in-atrial-fibrillation-nonpharmacologic-therapy

• Gutierrez, C., MD, & Blanchard, D. G., MD. (2011). Atrial Fibrillation: Diagnosis and Treatment. American Family Physician, 1(83), 1st ser., 61-68.

• Kumar, K. (2019, February 5). Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations. Retrieved from https://www.uptodate.com/contents/antiarrhythmic-drugs-to-maintain-sinus-rhythm-in-patients-with-atrial-fibrillation-recommendations/

• Kumar, K., MD. (2020, May 18). Overview of atrial fibrillation. Retrieved from https://www.uptodate.com/contents/overview-of-atrial-fibrillation.print?serach+atrial%20

• Lee, R., MD, Verrier, E., MD, & Knight, B. P., MD. (2020, February 12). Surgical ablation to prevent recurrent atrial fibrillation. Retrieved from https://www.uptodate.com.contents/surgical-ablation-to-prevent-recurrent-atrial-fibrillation.com

• Naccarelli, G. V., Ganz, L. I., & Manning, W. J. (2020, April 22). Atrial fibrillation: Cardioversion. Retrieved from https://www.uptodate.com/contents/atrial-fibrillation-cardioversion/print

• Olshansky, B., MD. (2019, February 21). The electrocardiogram in atrial fibrillation. Retrieved from https://www.uptodate.com/contetns/the-electrocardiogram-in-atrial-fibrillation/

• Passman, R., MD. (2020, February 25). Atrial fibrillation: Catheter ablation. Retrieved from https://www.uptodate.com/contents/atrial-fibrillation-catheter-ablation.com